Regulatory News:
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX),
a biotechnology company focused on improving cancer treatments by
targeting the tumor microenvironment (TME), announced today the
appointment of four leading pancreatic cancer experts to its
Scientific Advisory Board (SAB). Led by the newly appointed Chair,
Dr. Jose Saro, the SAB will provide strategic and scientific
counsel to NOXXON’s clinical programs in this indication.
“These prominent research leaders bring long-standing clinical
expertise, cutting-edge scientific knowledge, and a track record of
successfully developing new drugs to treat this devastating
disease. They fully understand the challenges of developing new
drugs for pancreas cancer where the tumor microenvironment plays a
large role in resisting anti-cancer therapy. The NOXXON team looks
forward to working with this group and to applying their insights
to the advancement of the company’s clinical pipeline. The caliber
of this group speaks to the potential of NOX-A12 to address the
some of the key unmet medical needs in pancreatic cancer,” said
Aram Mangasarian, CEO of NOXXON.
The formation and composition of the SAB reflect NOXXON’s
clinical development strategy as the company prepares to initiate a
two-arm Phase 2 trial in pancreatic cancer in Europe and the US.
The study will test NOX-A12 plus an anti-PD1 antibody with two
different standard of care chemotherapy regimens in second-line
pancreatic cancer later this year.
“With the majority of our newly appointed SAB members coming
from top centers of excellence in research in the US, we are paving
the path forward for NOXXON to become more active in this important
region for pharmaceutical research and development,” said Dr.
Jarl Ulf Jungnelius, Senior Medical Advisor of NOXXON.
NOXXON plans to expand the profile of the Scientific Advisory
Board to other areas as it further develops its programs.
The members of NOXXON’s SAB for pancreatic cancer are listed
below. Biographies for each member will also be available on the
NOXXON website.
Chiorean, E. Gabriela, MD Professor of Medicine at
University of Washington School of Medicine Professor, Clinical
Research Division at Fred Hutchinson Cancer Research Center
Director, Gastrointestinal Oncology Program at UW/Seattle Cancer
Care Alliance Clinical Research Director, Gastrointestinal Oncology
at the UW Medicine/Fred Hutchinson Cancer Research Center
As a professor of medicine at the UW School of Medicine,
professor at the Fred Hutchinson Cancer Research Center and
attending physician at Seattle Cancer Care Alliance, Dr. Gabriela
Chiorean strives to improve the care for patients with pancreatic
and other gastrointestinal cancers. She leads early-stage as well
as Phase 2 and 3 clinical trials of new therapies for these
cancers, including new chemotherapies, immunotherapies and targeted
drugs. She also aims to identify biomarkers of cancer, such as
molecules in the blood, that could be developed into a minimally
invasive test for the early detection of cancers or precancers. Dr.
Chiorean works with collaborative groups of clinicians and
researchers to implement cutting-edge clinical trials for
pancreatic cancer patients. She chairs the Pancreatic Cancer
Sub-Committee for the SWOG Cancer Research Network, is vice chair
of the NCI Pancreatic Cancer Task Force, and chair of the
Pancreatic Cancer Research Team.
O’Reilly, Eileen M., MD Winthrop Rockefeller Endowed
Chair in Medical Oncology Section Head, Hepatopancreaticobiliary
& Neuroendocrine Cancers Co-Director Medical Initiatives, David
M. Rubenstein Center for Pancreatic Cancer Attending Physician,
Member, Memorial Sloan Kettering Cancer Center Professor of
Medicine, Weill Cornell Medical College
Dr. O’Reilly is a medical oncologist whose research and clinical
activities focus on treating pancreatic and hepatobiliary cancers.
Her research initiatives include integrating molecular and
genetic-based therapies into the treatment of pancreatic cancer,
developing adjuvant and neoadjuvant therapies, and identifying
biomarkers that may be used to select therapy. She is the principal
investigator of multiple Phase 1, 2 and 3 pancreatic cancer
clinical trials and has authored and co-authored more than 300
articles, editorials and book chapters.
Prof. Dr. Seufferlein, Thomas T. W. Professor of
Gastroenterology at the University of Ulm Vice Dean for Research at
the Medical Faculty of the University of Ulm Chair of the Committee
for Cancer Prevention of the German Cancer Aid President of the
German Cancer Society (Deutschen Krebsgesellschaft, DKG)
Spokesperson of the German Cancer Aid and the Association of the
Scientific Medical Societies in Germany (Arbeitsgemeinschaft der
Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) Editor
in Chief of the German Journal of Gastroenterology General
Secretary of the European Society for Digestive Oncology (ESDO)
Prof. Seufferlein has a particular interest in gastrointestinal
(GI) oncology and the molecular basis of GI cancers, in particular
pancreatic cancer, and pioneering the clinical use of novel
treatments. He has been an active member of working and leading
groups of the DKG and a spokesperson of the Certification
Commission of Visceral Oncology Centers of the DKG for several
years. His clinical and basic research interests include
compartment specific signaling in cancer, regulation of cellular
protein transport, tumor-host-interaction and the organization of
the tumor cell cytoskeleton and biomarkers. Prof. Seufferlein was
involved in setting up the German National Guidelines and the
European Society for Medical Oncology (ESMO) guidelines for the
diagnosis and treatment of pancreatic cancer. He has authored and
co-authored more than 300 scientific articles, reviews and
opinions.
Von Hoff, Daniel D., MD, FACP, FASCO, FAACR
Distinguished Professor and Executive Vice President, Molecular
Medicine Translational Genomics Research Institute (TGEN) Virginia
G. Piper Distinguished Chair for Innovative Cancer Research and
Chief Scientific Officer, Honor Health Research Institute Chair of
the Early Drug Development Committee, US Oncology Distinguished
Professor, Department of Medical Oncology and Therapeutic Research,
City of Hope Professor of Medicine, Mayo Clinic
Dr. Von Hoff’s major interest is in the development of new
anticancer agents, both in the clinic and in the laboratory. He and
his colleagues were involved in the beginning of the development of
many FDA approved agents we now use routinely, including:
mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine,
irinotecan, nelarabine, capecitabine, lapatinib, vismodegib,
nab-paclitaxel, nal-IRI, pexidartinib and others. His clinical
trial work has led to the approval of three of the four drugs
approved by the FDA for treatment of patients with advanced
pancreatic cancer. At present, he and his colleagues are
concentrating on the development of therapies for patients with
advanced pancreatic cancer.
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor
microenvironment (TME) and the cancer immunity cycle by breaking
the tumor protection barrier and blocking tumor repair. By
neutralizing chemokines in the tumor microenvironment, NOXXON’s
approach works in combination with other forms of treatment to
weaken tumor defenses against the immune system and enable greater
therapeutic impact. Building on extensive clinical experience and
safety data, the lead program NOX-A12 has delivered top-line data
from a Keytruda® combination trial in metastatic colorectal and
pancreatic cancer patients and further studies are being planned in
these indications. In September 2019 the company initiated an
additional trial with NOX-A12 in brain cancer in combination with
radiotherapy. The combination of NOX-A12 and radiotherapy has been
granted orphan drug status in the US and EU for the treatment of
certain brain cancers. The company’s second clinical-stage asset
NOX-E36 is a Phase 2 TME asset targeting the innate immune system.
NOXXON plans to test NOX‑E36 in patients with solid tumors both as
a monotherapy and in combination. Further information can be found
at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme
Corp
https://twitter.com/noxxon_pharma
https://www.linkedin.com/company/noxxon-pharma-ag
Disclaimer
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future
results of business segments, financial indicators, developments of
the financial situation or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking
statements as certain prognoses of actual future events and
developments. The company is neither responsible nor liable for
updating such information, which only represents the state of
affairs on the day of publication.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210208005622/en/
NOXXON Pharma N.V. Aram Mangasarian, Ph.D., Chief
Executive Officer Tel. +49 (0) 30 726247 0
amangasarian@noxxon.com
Trophic Communications Gretchen Schweitzer or Valeria
Fisher Tel. +49 (0) 172 861 8540 or +49 (0) 175 804 1816
noxxon@trophic.eu
NewCap Arthur Rouillé Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr